Literature DB >> 17015893

18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.

Ali Agool1, Bart W Schot, Pieter L Jager, Edo Vellenga.   

Abstract

UNLABELLED: Few diagnostic procedures are available to determine the degree of bone marrow cellularity and the numbers of cycling cells in patients with bone marrow disorders. Noninvasive imaging of the bone marrow compartment may be helpful. The PET tracer 3'-fluoro-3'-deoxy-L-thymidine (18F-FLT) has been developed recently. 18F-FLT uptake is related to the rate of DNA synthesis and increases with higher proliferation rates in many types of cancer. Background uptake of 18F-FLT in bone marrow is common. 18F-FLT PET might, therefore, visualize the high cycling activity of hematopoietic cells in the bone marrow compartment. Therefore, we investigated the feasibility of visualization and quantification of the activity of the bone marrow compartment with 18F-FLT PET to distinguish different hematologic disorders.
METHODS: Clinical and laboratory data of 18 patients with myelodysplasia (MDS), chronic myeloproliferative disorders, myelofibrosis, aplastic anemia, or multiple myeloma were correlated with the results of 18F-FLT PET using visual analysis and the standardized uptake value (SUV). Findings were compared with those of healthy control subjects (n = 14).
RESULTS: With SUV and visual analysis, a distinction could be made between MDS (n = 9), chronic myeloproliferative disorders (n = 3), and myelofibrosis (n = 3) compared with healthy control subjects. A significant increase in 18F-FLT uptake was observed in all of the studied patients with MDS and myeloproliferative disorders. In contrast, patients with myelofibrosis and aplastic anemia (n = 1) demonstrated a decline in bone marrow 18F-FLT uptake compared with healthy control subjects. Comparable results were observed in osteolytic lesions of patients with multiple myeloma (n = 2).
CONCLUSION: 18F-FLT PET can be used to visualize the proliferative activity of the bone marrow compartment and may be helpful to distinguish separate hematologic disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015893

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  40 in total

1.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

Review 2.  Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.

Authors:  Gary A Ulaner; C Ola Landgren
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

3.  Uptake decrease of proliferative PET tracer 18FLT in bone marrow after carbon ion therapy in lung cancer.

Authors:  Mitsuru Koizumi; Tsuneo Saga; Masayuki Inubushi; Toshimitsu Fukumura; Kyosan Yoshikawa; Naoyoshi Yamamoto; Mio Nakajima; Toshio Sugane; Masayuki Baba
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

Review 4.  Imaging haemopoietic stem cells and microenvironment dynamics through transplantation.

Authors:  Kirsten M Williams; Jennifer Holter Chakrabarty
Journal:  Lancet Haematol       Date:  2020-03       Impact factor: 18.959

5.  Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis.

Authors:  Yu-Xiang Ye; Claudia Calcagno; Tina Binderup; Gabriel Courties; Edmund J Keliher; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Jun Tang; Carlos Pérez-Medina; Venkatesh Mani; Seigo Ishino; Camilla Bardram Johnbeck; Ulrich Knigge; Zahi A Fayad; Peter Libby; Ralph Weissleder; Ahmed Tawakol; Shipra Dubey; Anthony P Belanger; Marcelo F Di Carli; Filip K Swirski; Andreas Kjaer; Willem J M Mulder; Matthias Nahrendorf
Journal:  Circ Res       Date:  2015-09-22       Impact factor: 17.367

6.  Pharmacoimaging of Blood-Brain Barrier Permeable (FDG) and Impermeable (FLT) Substrates After Intranasal (IN) Administration.

Authors:  Laura L Boles Ponto; Susan Walsh; Jiangeng Huang; Christine Mundt; Katherine Thede-Reynolds; G Leonard Watkins; John Sunderland; Michael Acevedo; Maureen Donovan
Journal:  AAPS J       Date:  2017-12-07       Impact factor: 4.009

7.  Copper-64 labeled liposomes for imaging bone marrow.

Authors:  Sang-Gyu Lee; Kishore Gangangari; Teja Muralidhar Kalidindi; Blesida Punzalan; Steven M Larson; Naga Vara Kishore Pillarsetty
Journal:  Nucl Med Biol       Date:  2016-08-27       Impact factor: 2.408

8.  Extramedullary haematopoiesis imaging with 18F-FLT PET.

Authors:  Ali Agool; Rudi A J O Dierckx; Joost T M de Wolf; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-29       Impact factor: 9.236

Review 9.  Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.

Authors:  Susanne Lütje; Jacky W J de Rooy; Sandra Croockewit; Emmeline Koedam; Wim J G Oyen; Reinier A Raymakers
Journal:  Ann Hematol       Date:  2009-12       Impact factor: 3.673

10.  Splenectomy normalizes hematocrit in murine polycythemia vera.

Authors:  Jan-Rung Mo; Anjili Mathur; Minilik Angagaw; Shuxia Zhao; Yuxun Wang; Diana Gargano; Alessandra DiBacco; Eric S Bachman
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.